126 related articles for article (PubMed ID: 19097993)
1. CD4-anchoring HIV-1 fusion inhibitor with enhanced potency and in vivo stability.
Ji C; Kopetzki E; Jekle A; Stubenrauch KG; Liu X; Zhang J; Rao E; Schlothauer T; Fischer S; Cammack N; Heilek G; Ries S; Sankuratri S
J Biol Chem; 2009 Feb; 284(8):5175-85. PubMed ID: 19097993
[TBL] [Abstract][Full Text] [Related]
2. CD4-BFFI: a novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potency.
Jekle A; Chow E; Kopetzki E; Ji C; Yan MJ; Nguyen R; Sankuratri S; Cammack N; Heilek G
Antiviral Res; 2009 Sep; 83(3):257-66. PubMed ID: 19559732
[TBL] [Abstract][Full Text] [Related]
3. Palmitic Acid Is a Novel CD4 Fusion Inhibitor That Blocks HIV Entry and Infection.
Lee DY; Lin X; Paskaleva EE; Liu Y; Puttamadappa SS; Thornber C; Drake JR; Habulin M; Shekhtman A; Canki M
AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1231-41. PubMed ID: 20001317
[TBL] [Abstract][Full Text] [Related]
4. Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1.
Kopetzki E; Jekle A; Ji C; Rao E; Zhang J; Fischer S; Cammack N; Sankuratri S; Heilek G
Virol J; 2008 May; 5():56. PubMed ID: 18452606
[TBL] [Abstract][Full Text] [Related]
5. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of CD4-anchoring bi-functional fusion inhibitor in monkeys.
Liu X; Ou YC; Zhang J; Ahene A; Clark D; Hsieh SC; Cooper M; Ji C
Pharm Res; 2014 Mar; 31(3):809-18. PubMed ID: 24065594
[TBL] [Abstract][Full Text] [Related]
7. Highly potent chimeric inhibitors targeting two steps of HIV cell entry.
Zhao B; Mankowski MK; Snyder BA; Ptak RG; Liwang PJ
J Biol Chem; 2011 Aug; 286(32):28370-81. PubMed ID: 21659523
[TBL] [Abstract][Full Text] [Related]
8. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP
Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
[TBL] [Abstract][Full Text] [Related]
10. An immunoglobulin fusion protein based on the gp120-CD4 receptor complex potently inhibits human immunodeficiency virus type 1 in vitro.
Vu JR; Fouts T; Bobb K; Burns J; McDermott B; Israel DI; Godfrey K; DeVico A
AIDS Res Hum Retroviruses; 2006 Jun; 22(6):477-90. PubMed ID: 16796521
[TBL] [Abstract][Full Text] [Related]
11. Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.
Liu L; Patel B; Ghanem MH; Bundoc V; Zheng Z; Morgan RA; Rosenberg SA; Dey B; Berger EA
J Virol; 2015 Jul; 89(13):6685-94. PubMed ID: 25878112
[TBL] [Abstract][Full Text] [Related]
12. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.
Heredia A; Gilliam B; Latinovic O; Le N; Bamba D; Devico A; Melikyan GB; Gallo RC; Redfield RR
Antimicrob Agents Chemother; 2007 Jul; 51(7):2489-96. PubMed ID: 17485501
[TBL] [Abstract][Full Text] [Related]
14. HbAHP-25, an In-Silico Designed Peptide, Inhibits HIV-1 Entry by Blocking gp120 Binding to CD4 Receptor.
Bashir T; Patgaonkar M; Kumar SC; Pasi A; Reddy KV
PLoS One; 2015; 10(4):e0124839. PubMed ID: 25915507
[TBL] [Abstract][Full Text] [Related]
15. Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines.
Moody MA; Liao HX; Alam SM; Scearce RM; Plonk MK; Kozink DM; Drinker MS; Zhang R; Xia SM; Sutherland LL; Tomaras GD; Giles IP; Kappes JC; Ochsenbauer-Jambor C; Edmonds TG; Soares M; Barbero G; Forthal DN; Landucci G; Chang C; King SW; Kavlie A; Denny TN; Hwang KK; Chen PP; Thorpe PE; Montefiori DC; Haynes BF
J Exp Med; 2010 Apr; 207(4):763-76. PubMed ID: 20368576
[TBL] [Abstract][Full Text] [Related]
16. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
[TBL] [Abstract][Full Text] [Related]
17. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
Panos G; Watson DC
Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
[TBL] [Abstract][Full Text] [Related]
18. P2X-selective purinergic antagonists are strong inhibitors of HIV-1 fusion during both cell-to-cell and cell-free infection.
Swartz TH; Esposito AM; Durham ND; Hartmann BM; Chen BK
J Virol; 2014 Oct; 88(19):11504-15. PubMed ID: 25031337
[TBL] [Abstract][Full Text] [Related]
19. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
[TBL] [Abstract][Full Text] [Related]
20. [Viral entry as therapeutic target. Current situation of entry inhibitors].
Arenzana-Seisdedos F
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
